Compare Stocks → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:INNTNASDAQ:ITRMNASDAQ:JAGXNASDAQ:SVRANASDAQ:VVUS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs76 shsITRMIterum Therapeutics$1.57-0.6%$1.51$0.62▼$2.50$25.80M2.36507,100 shs13,208 shsJAGXJaguar Health$0.17+1.2%$0.09$0.05▼$1.22$46.96M1.3550.88 million shs20.25 million shsSVRASavara$4.58-2.3%$4.96$1.77▼$5.70$632.73M0.77835,352 shs106,256 shsVVUSVIVUS$0.37$0.44▼$4.75$7.33M-0.841.44 million shs2.03 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.91%ITRMIterum Therapeutics+1.94%+8.97%-1.25%-20.20%+46.30%JAGXJaguar Health-6.61%-5.78%+133.66%+63.58%-69.84%SVRASavara-0.21%-9.11%-2.29%-5.06%+157.69%VVUSVIVUS0.00%0.00%0.00%0.00%0.00%One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics0.8834 of 5 stars3.52.00.00.00.60.00.6JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/ASVRASavara1.4748 of 5 stars3.51.00.00.01.91.70.6VVUSVIVUSN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00282.17% UpsideJAGXJaguar HealthN/AN/AN/AN/ASVRASavara3.00Buy$8.2079.04% UpsideVVUSVIVUSN/AN/AN/AN/ACurrent Analyst RatingsLatest JAGX, VVUS, SVRA, ITRM, and INNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.004/1/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/4/2024SVRASavaraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $16.002/15/2024SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AITRMIterum TherapeuticsN/AN/AN/AN/A($0.48) per shareN/AJAGXJaguar Health$9.76M4.81N/AN/A$0.07 per share2.43SVRASavaraN/AN/AN/AN/A$1.04 per shareN/AVVUSVIVUS$69.76M0.00N/AN/A($6.50) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AITRMIterum Therapeutics-$38.37M-$2.97N/AN/AN/AN/A-664.00%-87.64%5/10/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)SVRASavara-$54.70M-$0.33N/AN/AN/AN/A-46.27%-35.94%5/20/2024 (Estimated)VVUSVIVUS-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/ALatest JAGX, VVUS, SVRA, ITRM, and INNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ITRMIterum Therapeutics-$1.02-$0.94+$0.08-$0.94N/AN/A3/7/2024Q4 2023SVRASavara-$0.11-$0.09+$0.02-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINNTInnovate BiopharmaceuticalsN/A0.350.35ITRMIterum Therapeutics3.631.891.89JAGXJaguar Health6.332.001.34SVRASavara0.1915.6615.66VVUSVIVUSN/A0.430.28OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINNTInnovate Biopharmaceuticals5.88%ITRMIterum Therapeutics9.21%JAGXJaguar Health12.04%SVRASavara87.93%VVUSVIVUS7.32%Insider OwnershipCompanyInsider OwnershipINNTInnovate Biopharmaceuticals7.90%ITRMIterum Therapeutics5.40%JAGXJaguar Health0.02%SVRASavara4.58%VVUSVIVUS12.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableITRMIterum Therapeutics1416.43 million15.54 millionNot OptionableJAGXJaguar Health49276.22 million276.16 millionNo DataSVRASavaraN/A138.15 million131.82 millionOptionableVVUSVIVUS5717.87 millionN/AOptionableJAGX, VVUS, SVRA, ITRM, and INNT HeadlinesSourceHeadlineVIVUS Provides Update on Pipeline and Program Milestonesmarkets.businessinsider.com - January 8 at 10:04 AMShark research group to build new global headquarters in Jacksonville with help from state fundingactionnewsjax.com - June 26 at 9:16 AMMetaview announces Answers, the world's first conversational AI for the interview processit.tmcnet.com - May 25 at 11:10 AMPancrelipase (CAS 53608-75-6) Market 2023 | Industry Growth ... - StreetBuzznews.google.com - May 12 at 2:58 AMExploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journalnews.google.com - May 12 at 2:58 AMExtensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPRnews.google.com - May 11 at 8:54 AMErectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:54 AMMilestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswirenews.google.com - May 11 at 8:54 AMAnti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journalnews.google.com - May 11 at 3:54 AMAnti Obesity Drugs Market Future Industry Scope for New ... - Digital Journalnews.google.com - May 11 at 3:54 AMThis Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolutionnews.google.com - May 10 at 12:51 PMProstatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journalnews.google.com - May 9 at 6:48 AMThis 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuitnews.google.com - May 7 at 8:20 PMPorsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuitnews.google.com - May 6 at 3:22 PMIncreasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPRnews.google.com - May 5 at 1:45 PMNonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journalnews.google.com - May 5 at 7:44 AMA Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpostnews.google.com - May 2 at 10:24 AMIntraoperative Ultrasound Market Latest Trends, Techniques and Applications|2023-2030 - openPRnews.google.com - April 28 at 9:38 AMBuild Your Own Case Study | Obesity: Treating the Whole Patient - Healionews.google.com - April 27 at 8:14 PMBladder Cancer Market Demand in Various industries and Significant for Various Regions|2023-2030 - openPRnews.google.com - April 27 at 3:10 PMPediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insightsnews.google.com - April 27 at 10:10 AMGlobal Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPRnews.google.com - April 26 at 7:33 AMNon-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPRnews.google.com - April 25 at 2:02 AMWhat to Know About Obesity and Bone Health - Health Centralnews.google.com - April 24 at 4:02 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsInnovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.SavaraNASDAQ:SVRASavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.VIVUSNASDAQ:VVUSVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.